STAT+: House lawmaker probes PBMs for ‘punitive’ audits of independent pharmacies
A House lawmaker is investigating whether the three largest PMS targeted independent pharmacies withretaliatory audits.
Read at STAT News · 26 October 2026 at 16:26
STAT+: House lawmaker probes PBMs for ‘punitive’ audits of independent pharmacies
All coverage of this event, automatically grouped from multiple independent sources.
Last updated: 26 October 2026 at 18:41 · 7 articles · 1 sources
STAT+: GSK sees its return to cancer start to pay off
A decade ago, GSK was out of oncology. It could soon pick up approval for its sixth cancer drug.
Read at STAT News · 26 October 2026 at 16:20
STAT+: Merck ADC drug cut risk of death by one-third in advanced endometrial cancer
A Phase 3 trial of a targeted drug developed by Merck and China’s Kelun-Biotech cut by one-third the risk of death in patients with advanced endometrial cancer.
Read at STAT News · 26 October 2026 at 15:30
STAT+: Rising premiums, a sad Medicaid gathering, and a new fraud crackdown
The cost of health insurance is surging, and CMS presses ahead with a new fraud crackdown.
Read at STAT News · 26 October 2026 at 14:38
STAT+: Incyte pancreatic cancer medicine induces lasting tumor responses, company says at ESMO
A targeted drug from Incyte, when used in combination with chemotherapy, induced lasting tumor responses in certain patients with pancreatic cancer.
Read at STAT News · 26 October 2026 at 13:57
STAT+: Five biotech updates to read after ESMO this weekend
Moderna and Merck are racing to submit their personalized cancer vaccine for FDA approval, expected in 2027, according to Moderna CEO Stéphane Bancel.
Read at STAT News · 26 October 2026 at 13:38
STAT+: Pharmalittle: We’re reading about a Roche lung cancer drug, a Bristol CAR-T trial death, and more
Bristol Myers Squibb reported that one patient died after receiving its investigational CAR-T therapy in an early autoimmune trial
Read at STAT News · 26 October 2026 at 13:37